For U.S. Healthcare Professionals

Questions? Call 855-4ADYNOVATE

Now approved FOR THE TREATMENT OF HEMOPHILIA A
IN CHILDREN UNDER 12 AND IN SURGICAL PROCEDURES

View Data for Children Under 12 See Interim Surgical Data

ADYNOVATE® Proven prophylaxis +
simple, twice-weekly dosing schedule =

moments their way
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] allows patients to infuse on the same 2 days every week.1
  • Efficacy

    Learn about the efficacy of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] in children and adults, and see the interim surgical data.

    See Data
  • Dosing & Administration

    Get information about the simple, twice-weekly dosing schedule, available dosing strengths, the BAXJECT® II Hi-Flow Needleless Transfer Device, and the BAXJECT III® Reconstitution System.1

    Learn More
  • Safety

    Learn about safety data from the ADYNOVATE clinical trials.

    See Data
  • Dedicated Support

    Shire is proud to provide a variety of programs and resources for the bleeding disorders community.

    Take Me There
  • The Science

    Learn more about the extended terminal
    half-life of ADYNOVATE.1

    Explore the Science
Detailed Important Risk Information
Prescribing Information (PI)
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] Important Information
Indications

ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is a human antihemophilic factor indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use

ADYNOVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION


Click here for ADYNOVATE full Prescribing Information.



ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • Control and prevention of bleeding episodes.
  • Perioperative management.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Neutralizing Antibodies
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Click here for ADVATE full Prescribing Information.